Zahid Rashid, MD
Gastroenterology · Petersburg, VANPI 1255396164
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 25.7% of the total. Reporting peaked in 2023 at $1,169 and has fallen 93.0% since, to $82 in 2025. That places this record below the midpoint for gastroenterology clinicians in VA, where the typical reported total is $3,407.
Across 210 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Ironwood Pharmaceuticals, Inc$400
- Sanofi$308
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$300
- Bristol Myers Squibb$294
- Johnson & Johnson$241
- plus $1K from 20 others
Across 120 payments — averaging $4281.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$231K
- AbbVie$228K
- Eli Lilly$32K
- Bristol Myers Squibb$22K
What the payments were for
- Food & beverage$3,973100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $1,023 |
| Ironwood Pharmaceuticals, Inc | 41 | $400 |
| Sanofi | 13 | $308 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $300 |
| Bristol Myers Squibb | 22 | $294 |
| Johnson & Johnson(2 entities) | 5 | $241 |
| Ardelyx, Inc. | 11 | $185 |
| Seagen Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Pharming Healthcare, Inc. | 1 | $125 |
| Blueprint Medicines Corporation | 1 | $122 |
| Nestle Healthcare Nutrition Inc. | 7 | $120 |
| Gilead | 8 | $115 |
| Boehringer Ingelheim | 1 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Phathom Pharmaceuticals, Inc. | 4 | $58 |
| Merck | 3 | $54 |
| Enterra Medical, Inc. | 1 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Celltrion USA Inc. | 1 | $29 |
| Ambu Inc. | 1 | $27 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,973 in reported general payments places this provider in the 50th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 108 | $110,361 |
| IbsrelaTenapanor Hcl | 29 | $56,007 |
| CreonLipase/Protease/Amylase | 29 | $42,974 |
| Mesalamine | 23 | $8,615 |
| TrulancePlecanatide | 12 | $6,964 |
| Colestipol Hcl | 53 | $4,685 |
| Esomeprazole Magnesium | 26 | $2,943 |
| Omeprazole | 146 | $2,367 |
| Pantoprazole Sodium | 143 | $2,150 |
| Sucralfate | 14 | $1,776 |
| Dicyclomine Hcl | 76 | $1,342 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 81 | $1,284 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 81 | $1,235 |
| Famotidine | 54 | $959 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 21 | $335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $1,023 | $153,335137 claims |
| Ardelyx, Inc.Ibsrela | $185 | $56,00729 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $300 | $6,96412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 473 gastroenterology providers in Virginia.
Other gastroenterology in Petersburg
- Larry ClarkLynchburg$1.2M
- Arun SanyalRichmond$855K
- Mitchell ShiffmanNewport News$635K
- Bryan SauerCharlottesville$540K
- Michael RyanNorfolk$335K
- Brian WentworthCharlottesville$276K
- Vanessa ShamiCharlottesville$210K
- Ali SiddiquiFairfax$167K
- Michael FuchsRichmond$126K
- Michael ManetasRichmond$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.